Viridian Therapeutics, Inc. is a biotechnology company dedicated to advancing the treatment of rare autoimmune diseases. It leverages its expertise in antibody discovery and engineering to develop optimized therapeutics, with a primary focus on Thyroid Eye Disease (TED). Viridian operates a robust pipeline and participates in clinical trials aimed at improving patient care by providing innovative solutions. The company is committed to gathering talented individuals to drive forward their mission of enhancing therapeutic options for those affected by rare autoimmune conditions.